STK17B was also identified in an in vivo CRISPR screen in tumor-bearing animals to identify novel cancer immunotherapy targets, where STK17B-depleted T cells were highly enriched in the tumor-infiltrating lymphocyte population (9). The gene discussed is STK17B; the disease is neoplasm.